Icecure Medical is trading at $1.16, up 5.45%, with no clear catalyst identified for the October 12 move.
- No new company announcement was identified; the latest listed release was an October 6 update adding a clinical site to the ChoICE study.
- Available market context does not establish a broad-market cause. Shares closed at $1.10 on October 9 after several down sessions, based on the supplied price context.